Regulation of store-operated Ca2+ entry in pulmonary artery smooth muscle cells.
Store-operated Ca2+ entry (SOCE) is an important mechanism for Ca2+ influx in smooth muscle cells; however the activation and regulation of this influx pathway are incompletely understood. In the present study we have examined the effect of several protein kinases in regulating SOCE in pulmonary artery smooth muscle cells (PASMCs) of the rat. Inhibition of protein kinase C with chelerythrine (3microM) potentiated SOCE by 47+/-2%, while the tyrosine kinase inhibitors genistein (100microM) and tyrphostin 23 (100microM) caused a significant reduction in SOCE of 55+/-9% and 43+/-7%, respectively. It has been proposed that Ca2+-insensitive phospholipase A(2) (iPLA(2)) is involved in the activation of SOCE in many different cell types. The iPLA(2) inhibitor, bromoenol lactone had no effect on SOCE, suggesting that this mechanism was not involved in the activation of the pathway. The calmodulin antagonists, calmidazolium (CMZ) (10microM) and W-7 (10microM) appeared to potentiate SOCE in PASMCs. Further investigation established that CMZ was actually activating a Ca2+ influx pathway that was independent of the filling state of the sarcoplasmic reticulum. The CMZ-activated Ca2+ influx was blocked by Gd3+ (10microM), but unaffected by 2-APB (75microM), indicating a pharmacological profile distinct from the classical SOCE pathway.
McElroy
Stuart P
SP
Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, 27 Taylor Street, Glasgow G4 0NR, United Kingdom.
Drummond
Robert M
RM
Gurney
Alison M
AM
D000818:Animals; D053119:Benzophenanthridines / Q000494:pharmacology; D001896:Boron Compounds / Q000494:pharmacology; D002118:Calcium / Q000378:metabolism*; D002147:Calmodulin / Q000378:metabolism*; D002478:Cells, Cultured; D004791:Enzyme Inhibitors / Q000494:pharmacology; D019833:Genistein / Q000494:pharmacology; D007093:Imidazoles / Q000494:pharmacology; D017136:Ion Transport / Q000187:drug effects; D008297:Male; D032389:Myocytes, Smooth Muscle / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology; D009281:Naphthalenes / Q000494:pharmacology; D054467:Phospholipases A2 / Q000378:metabolism; D011493:Protein Kinase C / Q000378:metabolism*; D011505:Protein-Tyrosine Kinases / Q000378:metabolism*; D011651:Pulmonary Artery / Q000473:pathology; D011753:Pyrones / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D013449:Sulfonamides / Q000494:pharmacology; D020032:Tyrphostins / Q000494:pharmacology
D053119:Benzophenanthridines; D001896:Boron Compounds; D002147:Calmodulin; D004791:Enzyme Inhibitors; D007093:Imidazoles; D009281:Naphthalenes; D011753:Pyrones; D013449:Sulfonamides; D020032:Tyrphostins; C031938:calmidazolium; C017967:W 7; C068314:6-(bromomethylene)tetrahydro-3-(1-naphthaleneyl)-2H-pyran-2-one; D019833:Genistein; C016299:chelerythrine; C109986:2-aminoethoxydiphenyl borate; D011505:Protein-Tyrosine Kinases; D011493:Protein Kinase C; D054467:Phospholipases A2; C060641:tyrphostin A23; D002118:Calcium